StockNews.com cut shares of Greenlight Capital Re (NASDAQ:GLRE – Free Report) from a buy rating to a hold rating in a research report released on Wednesday morning.
Greenlight Capital Re Price Performance
Shares of GLRE stock opened at $14.13 on Wednesday. The stock has a 50 day moving average of $14.42 and a two-hundred day moving average of $13.77. The company has a current ratio of 3.02, a quick ratio of 3.02 and a debt-to-equity ratio of 0.09. Greenlight Capital Re has a 12 month low of $10.95 and a 12 month high of $15.82. The company has a market capitalization of $492.18 million, a P/E ratio of 5.61 and a beta of 0.89.
Greenlight Capital Re (NASDAQ:GLRE – Get Free Report) last posted its earnings results on Monday, November 4th. The financial services provider reported $1.01 EPS for the quarter, topping the consensus estimate of $0.65 by $0.36. The business had revenue of $188.01 million during the quarter. Greenlight Capital Re had a return on equity of 13.95% and a net margin of 12.38%. During the same quarter last year, the business earned $0.39 EPS.
Hedge Funds Weigh In On Greenlight Capital Re
About Greenlight Capital Re
Greenlight Capital Re, Ltd., through its subsidiaries, operates as a property and casualty reinsurance company worldwide. The company offers various property reinsurance products and services, including automobile physical damage, personal lines, and commercial lines. It also provides casualty reinsurance products and services comprising general liability, motor liability, professional liability, and worker's compensation; and accident and health, transactional liability, mortgage insurance, surety, trade credit, marine, and energy, as well as other specialty products, such as aviation, crop, cyber, political, and terrorism products.
Featured Stories
- Five stocks we like better than Greenlight Capital Re
- How to Read Stock Charts for Beginners
- 3 Defensive Stocks Analysts Are Bullish on to Kick Off the Year
- What is a buyback in stocks? A comprehensive guide for investors
- Vistra Corp: Could 2025 Continue Its Streak of Outperformance?
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Vertex’s Pain Drug: Big Pharma’s Next Major Success?
Receive News & Ratings for Greenlight Capital Re Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenlight Capital Re and related companies with MarketBeat.com's FREE daily email newsletter.